CMPX

Compass Therapeutics Inc.

CMPX.US compasstherapeutics.com + Research + Basket
CIK 0001738021
Employees 39
Phone 617 500 8099
Fiscal year end December
IPO Apr 05, 2021
Address 80 Guest Street, Boston, MA, United States, 02135
0.76
+0.01 (+1.73%)
USD · NASDAQ
52-week range
0.73
6.88
Trading at 0% of the 52-week range
Market Cap
134.56M
P/E Ratio
0.00
Forward P/E
0.00
Book Value
0.92
Div. Yield
N/A
% Institutions
88.45%
% Insiders
12.47%

1 Year

-81.5%

3 Year

-57.0%

10 Year

-90.9%
Description

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization. It also develops CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies; and CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Actions

Add an action for CMPX.US, or sign in to see your action list.

People

▼

Directors & Officers

Name Title Year Born
Dr. Thomas J. Schuetz M.D., Ph.D. CEO & Vice Chairman 1961
Mr. Barry Shin J.D., M.B.A. Chief Financial Officer 1972
Mr. Jonathan E. Anderman J.D. Senior VP, General Counsel & Corporate Secretary 1983
Mr. Neil L. Lerner CPA Senior VP & Chief Accounting Officer 1967
Mr. Bing Gong Ph.D. Chief Scientific Officer 1976
Anna Gifford Senior Manager of Communications & Chief of Staff NA
Ms. Karin Herrera B.A. Senior VP & Head of Clinical Operations NA
Dr. James Kranz Ph.D. VP and Head of Chemistry Manufacturing & Controls NA
Dr. Cynthia A. Sirard M.D., Ph.D. Chief Medical Officer 1970
Mr. Arjun Prasad M.B.A., M.P.H. Chief Commercial Officer 1978

Insider Trading

Open insider trading
Date Insider Name Title Transaction Type Shares Price Value SEC
May 27, 2025 Thomas J Schuetz N/A Purchase 10.00K $2.11 $21.10K SEC

Shareholders

▼

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
TANG CAPITAL MANAGEMENT LLC 17.99M Jun 30, 2026 9.99% $1.79 7.15%
Orbimed Advisors LLC 15.22M Jun 30, 2026 8.45% $0.62 0.00%
Suvretta Capital Management, LLC 14.10M Jun 30, 2026 7.83% $0.56 -1.44%
BlackRock Inc 11.28M Jun 30, 2026 6.26% $0.00 18.68%
State Street Corp 9.95M Jun 30, 2026 5.53% $0.00 48.67%
Enavate Sciences GP, LLC 7.79M Jun 30, 2026 4.32% $4.94 0.00%
Vivo Capital, LLC 7.76M Jun 30, 2026 4.31% $1.55 -18.74%
Vanguard Capital Management, LLC 6.12M Jun 30, 2026 3.40% $0.00 1.35%
Palo Alto Investors, LLC 5.83M Jun 30, 2026 3.24% $1.76 285.06%
Millennium Management LLC 4.71M Jun 30, 2026 2.62% $0.00 456.98%
Geode Capital Management, LLC 3.82M Jun 30, 2026 2.12% $0.00 6.99%
Vanguard Portfolio Management, LLC 3.77M Jun 30, 2026 2.09% $0.00 248.31%
Qube Research & Technologies 3.69M Jun 30, 2026 2.05% $0.01 44.59%
Blue Owl Capital Holdings LP 3.62M Jun 30, 2026 2.01% $1.19 23.20%
Citadel Advisors Llc 3.57M Jun 30, 2026 1.98% $0.00 394.96%
The Goldman Sachs Group Inc 3.53M Jun 30, 2026 1.96% $0.00 76.96%
Rock Springs Capital Management LP 3.52M Jun 30, 2026 1.96% $0.38 6.64%
AQR Capital Management LLC 3.51M Jun 30, 2026 1.95% $0.00 1,650.82%
Birchview Capital, LP 1.68M Jun 30, 2026 0.93% $1.72 14.27%
Kingdon Capital Management LLC 1.40M Jun 30, 2026 0.78% $0.31 0.00%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 State Street® SPDR® S&P® Biotech ETF 4.84M 2.69% ▼ 1.88% Sep 30, 2026
2 Vanguard MStar Total Stk Mkt Idx Invest 4.19M 2.33% ▲ 0.00% Sep 30, 2026
3 iShares Russell 2000 ETF 3.48M 1.93% ▼ 1.14% Sep 30, 2026
4 Fidelity Enhanced Small Cap Core ETF 1.61M 0.90% ▲ 0.21% Sep 30, 2026
5 Fidelity Small Cap Index 1.43M 0.79% ▼ 0.12% Jul 31, 2026
6 iShares Russell 2000 Value ETF 1.22M 0.68% ▲ 0.15% Sep 30, 2026
7 Vanguard Explorer Inv 962.80K 0.53% ▲ 0.00% Jun 30, 2026
8 Fidelity Extended Market Index 819.62K 0.46% ▼ 2.25% Aug 31, 2026
9 Vanguard VIF Small Co Gr 775.00K 0.43% ▲ 0.00% Jun 30, 2026
10 Vanguard Russell 2000 ETF 758.75K 0.42% ▲ 0.56% Sep 30, 2026

Financial Highlights

▼
Market Cap: $134.56M
EBITDA: $-81.01M
Book Value: $0.92
Earnings/Share: $-0.39
Profit Margin: 0.00%
Operating Margin: 0.00%
ROA (TTM): -33.03%
ROE (TTM): -56.66%
Revenue (TTM): $0.00
Revenue/Share (TTM): $0.00
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 0.00%

Valuation Metrics

Enterprise Value: $-33.20M
Trailing P/E: 0.00
Forward P/E: 0.00

Shares Statistics

Shares Outstanding: 180.09M
Shares Float: 132.42M
% Insiders: 12.47%
% Institutions: 88.45%
Short % Float: 26.79%

Stock Price History

▼

1 Year Price History

3 Years Price History

10 Years Price History

Max Price History

Financial Charts

▼
Open balance sheet Open capital intensity Download Financials (Excel)

Revenue, Net Income & Operating Cash Flow (Yearly)

Change % vs Prior Year

Revenue, Net Income & Operating Cash Flow (Quarterly)

Change % vs Prior Quarter

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

▼
Open full waterfall Open balance sheet
Line Item
Step Type
Value
Revenue
adjust
$0.00
Cost of Goods Sold
adjust
$-1.47M
Gross Profit
subtotal
$-1.47M
SG&A
adjust
$-16.87M
R&D
adjust
$-55.97M
Operating Income
subtotal
$-72.84M
Other / Non-Operating Items
adjust
$6.35M
Net Income
subtotal
$-66.49M

Earnings Per Share (EPS) History

▼

Financial Ratios

▼

📦 Raw API Data (JSON Explorer)

▼

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about CMPX.US!